Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 4:25 AM
Ignite Modification Date:
2025-12-26 @ 3:28 AM
NCT ID:
NCT03626220
Group ID:
EG000
Title:
The Acupuncture Group
Description:
Acupuncture treatment will be performed for 9 weeks. The frequency of acupuncture will be twice a week for the first six weeks, and once a week for the following three weeks. 30 minutes needling at each treatment. Acupuncture points include Baihui(GV20), Qihai(CV6), Quchi(LI11), Hegu(LI4), Neiguan(P6), and Shenmen(HT7) for upper limbs. For palm numbness, choose two acupoints to use in turn; use Weizhong(BL40), Sanyinjiao(SP6), and Zusanli(ST36) for lower limbs. For the acupuncture points, Taixi(KI3) and Yongquan(K1) should be added for foot numbness. "De qi" sensation, such as soreness, numbness, pain, etc. will be achieved at each acupoints .
acupuncture: More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi's Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, LTD., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints
Deaths Number Affected:
0
Deaths Number At Risk:
None
Serious Number Affected:
0
Serious Number At Risk:
10
Other Number Affected:
0
Other Number At Risk:
10
Study:
NCT03626220
Results Section:
NCT03626220
Adverse Events Module:
NCT03626220